arrow
M

Masako Ikemura

Toranomon Hospital
H指数:23
被引数:2,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma

组蛋白甲基转移酶SUV39H2抑制剂与聚(ADP-核糖)聚合酶抑制剂联合应用对子宫平滑肌肉瘤的合成致死效应

2025-12-160
OAAI
Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas

串联组学分析揭示了复发性脑膜瘤恶性转化的分子特征

2025-11-180
OAAI
Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival

分子水平上对接受立体定向放射手术治疗的脑膜瘤预后模型的洞察:1q获得对肿瘤控制和生存的负面影响

2025-11-180
OAAI
Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab

优化铂类耐药卵巢透明细胞癌的治疗: 吉西他滨和贝伐单抗联合治疗的疗效

Cancer
IF5.1
2025-08-310
OAAI
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin

整合的基因组/表观基因组分析对透明细胞卵巢癌的亚型进行分层,突出其细胞起源

2024-08-131
OAAI
Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration

2型神经纤维瘤病患者的脑膜瘤主要包括以巨噬细胞浸润为特征的 “免疫原性亚型” 肿瘤

2023-09-263
OAAI
Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index
2022-05-1513
OA